ArticleInvestigational new drugs2016

Phase I, dose-escalating study of elisidepsin (Irvalec(®)), a plasma membrane-disrupting marine antitumor agent, in combination with erlotinib in patients with advanced malignant solid tumors.

Sanjay Goel et al.PubMed ↗Publisher ↗

No numbers read from the abstract.